SC
CGON icon

Stempoint Capital’s CG Oncology CGON Stock Holding History

Stempoint Capital’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Sell
159,349
-46,273
-23% -$3.02M 1.95% 18
2026
Q1 		$13.9M Buy
+205,622
New +$11.7M 2.66% 10
2025
Q4 		– Sell
-63,019
Closed -$2.54M – 90
2025
Q3 		$2.54M Buy
+63,019
New +$1.83M 0.51% 46
2025
Q2 		– Sell
-289,823
Closed -$7.1M – 59
2025
Q1 		$7.1M Buy
+289,823
New +$8.15M 2.26% 16
2024
Q2 		– Sell
-40,723
Closed -$1.79M – 53
2024
Q1 		$1.79M Buy
+40,723
New +$1.66M 0.47% 39

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Stempoint Capital's CGON Position: Q2 2026 in Review

Stempoint Capital reduced its CG Oncology (CGON) stake by 23% in Q2 2026, selling an estimated $3.02M and leaving 159,349 shares worth $11.3M. The position accounts for 1.95% of the portfolio, ranked #18.

Stempoint Capital first reported a position in CGON in Q1 2024 and has held it in 5 quarters since. The position peaked at $13.9M in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Stempoint Capital held 159,349 shares of CG Oncology worth $11.3M as of Q2 2026.
  • Stempoint Capital sold 46,273 CG Oncology shares in Q2 2026, an estimated $3.02M.
  • CG Oncology made up 1.95% of Stempoint Capital's portfolio in Q2 2026, its #18 holding.
  • Stempoint Capital first reported a position in CG Oncology in Q1 2024 and has held it in 5 quarters since.
  • Stempoint Capital's CG Oncology position peaked at $13.9M in Q1 2026.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.